SR26334: carboxylic acid derivative clopidogrel metabolite; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9861403 |
| SCHEMBL ID | 4770 |
| MeSH ID | M0511863 |
| Synonym |
|---|
| AKOS015899956 |
| 144457-28-3 |
| DCASRSISIKYPDD-AWEZNQCLSA-N , |
| (s)-(+)-alpha-(2-chlorophenyl)-6,7-dihydro-4h-thieno[3,2-c]pyridine-5-acetic acid |
| SCHEMBL4770 |
| sr26334 |
| (+)-(s)-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4h)-acetic acid |
| (2s)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno(3,2-c)pyridin-5(4h)-yl)acetic acid |
| clopidogrel besilate impurity a [ep impurity] |
| thieno(3,2-c)pyridine-5(4h)-acetic acid, .alpha.-(2-chlorophenyl)-6,7-dihydro-, (.alpha.s)- |
| clopidogrel hydrogen sulfate impurity a [ep impurity] |
| clopidogrel hydrochloride impurity a [ep impurity] |
| sr-26334 |
| 1b9z4634cd , |
| unii-1b9z4634cd |
| thieno(3,2-c)pyridine-5(4h)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, (alphas)- |
| (s)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetic acid |
| (s)-a-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h)-acetic acid |
| J-007952 |
| (s)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)aceticacid |
| DTXSID10891466 |
| (2s)-2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetic acid |
| Q27252189 |
| A884808 |
| discontinued see c587235 |
| (s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h)-acetic acid |
| CS-0165247 |
| (s)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetic acid? (clopidogrel impurity pound(c) |
| PD054158 |
| thieno[3,2-c]pyridine-5(4h)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, (alphas)- |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The measured pharmacokinetic parameters did not differ significantly between the clopidogrel besylate and clopidogrel bisulfate groups." | ( Comparative pharmacokinetics/pharmacodynamics of clopidogrel besylate and clopidogrel bisulfate in healthy Korean subjects. Cho, JY; Jang, IJ; Kim, BH; Kim, JR; Lim, KS; Shin, HS; Shin, SG; Yoon, SH; Yu, KS, 2012) | 0.38 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Two randomized, single dose, 2-period, 2-sequence crossover studies were conducted to evaluate the comparative bioavailability of two clopidogrel formulations under fasting and fed conditions." | ( Comparative bioavailability of two oral formulations of clopidogrel: determination of clopidogrel and its carboxylic acid metabolite (SR26334) under fasting and fed conditions in healthy subjects. Breznik, M; Brvar, N; Cvitkovič Marčič, L; Grabnar, I; Lachance, S; Lévesque, A; Mateovič-Rojnik, T; Merslavič, M, 2014) | 0.61 |
| Pathway | Proteins | Compounds |
|---|---|---|
| Clopidogrel Pathway, Pharmacokinetics | 10 | 6 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.26) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (50.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||